Titan Biotech Ltd — Dividend/Bonus, 30-05-2026: Corp. Action

Titan Biotech's Board has approved the financial results for the quarter and year ended March 31. For the full year, standalone revenue stood at 206.19 Cr, with profit at 27.45 Cr. The Board also proposed a dividend of Rs. 0.50 per equity share, which requires shareholder approval. Additionally, M/s Sanjay Kumar Garg & Associates were re-appointed as Cost Auditors, and a scrutinizer was appointed for the upcoming Annual General Meeting.